NVO
Novo Nordisk A/S
NYSEUSDEQUITY
Healthcare
DELAYED
Sell
-41/100
Last price
37.53
▼ 0.01 (0.03%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
37.43
Prev close
37.54
Day high
37.53
Day low
36.85
Volume
13.68M
Market cap
$165.67B
P/E (TTM)
9.18
52W range
35.12 – 64.16
Day trading desk
Gap from prior close
-0.29%
Prior close 37.54
VWAP
37.32
+0.56% from price
Relative volume
2.62×
Unusually busy
Session range
2.54%
36.85 – 37.78
Position in range
73%
Near session high
ATR (14D)
1.01
2.69% of price
Prior day high
37.61
PDH
Prior day low
36.86
PDL
Bid / ask spread
—
Quote not published
Session volume
32.63M
Avg 12.47M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.04%
-4.0%
1M
-19.46%
-20.6%
3M
-23.24%
-27.8%
6M
+1.68%
-16.5%
YTD
-26.24%
-40.5%
1Y
-37.06%
-53.5%
3Y
-58.73%
-141.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NVO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
132.84K
Total on file
Fundamentals
Market cap$165.67B
Enterprise value$261.33B
Revenue (TTM)$329.43B
Gross profit$270.09B
EBITDA$173.68B
Net income$116.44B
EPS (TTM)$4.09
Free cash flow$37.67B
Total cash$44.98B
Total debt$140.13B
Book value / share$7.58
Shares outstanding3.34B
Float3.17B
Short % of float0.83%
Dividend yield4.79%
Beta (5Y)0.38
Valuation & profitability ratios
Trailing P/E9.18
Forward P/E11.28
PEG ratio4.33
Price / sales—
Price / book4.95
EV / revenue0.79
EV / EBITDA1.51
Gross margin81.99%
Operating margin42.54%
Profit margin35.35%
Return on equity59.81%
Return on assets18.73%
Debt / equity63.33
Current ratio0.87
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $309.06B | $290.40B | $232.26B | $176.95B | +6.4% |
| Operating revenue | $729.42B | $680.56B | $608.64B | $455.69B | +7.2% |
| Cost of revenue | $58.79B | $44.52B | $35.77B | $28.45B | +32.0% |
| Gross profit | $250.28B | $245.88B | $196.50B | $148.51B | +1.8% |
| Research & development | $52.04B | $48.06B | $32.44B | $24.05B | +8.3% |
| Selling, general & admin | $70.28B | $67.38B | $61.60B | $50.68B | +4.3% |
| Total operating expense | $122.62B | $117.54B | $93.92B | $73.70B | +4.3% |
| Operating income | $127.66B | $128.34B | $102.57B | $74.81B | -0.5% |
| Net interest income | -$3.18B | -$91.00M | $330.00M | -$320.00M | -3,393.4% |
| Pre-tax income | $130.54B | $127.19B | $104.67B | $69.06B | +2.6% |
| Tax provision | $28.11B | $26.20B | $20.99B | $13.54B | +7.3% |
| Net income | $102.43B | $100.99B | $83.68B | $55.52B | +1.4% |
| Net income to common | $102.43B | $100.99B | $83.68B | $55.52B | +1.4% |
| Basic EPS | 23.06 | 22.67 | 18.67 | 12.26 | +1.7% |
| Diluted EPS | 23.03 | 22.63 | 18.62 | 12.22 | +1.8% |
| EBIT | $134.75B | $128.83B | $105.22B | $69.44B | +4.6% |
| EBITDA | $149.41B | $137.38B | $114.63B | $76.80B | +8.8% |
| Basic shares | 4.44B | 4.45B | 4.48B | 4.53B | -0.3% |
| Diluted shares | 4.45B | 4.46B | 4.49B | 4.54B | -0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $26.46B | $15.65B | $14.39B | $12.65B | +69.0% |
| Cash & short-term investments | $26.96B | $26.31B | $30.23B | $23.57B | +2.5% |
| Accounts receivable | $70.86B | $71.95B | $64.77B | $50.56B | -1.5% |
| Inventory | $49.62B | $40.85B | $31.81B | $24.39B | +21.5% |
| Total current assets | $172.45B | $161.79B | $139.65B | $108.19B | +6.6% |
| Property, plant & equipment | $208.38B | $161.68B | $90.96B | $66.67B | +28.9% |
| Goodwill & intangibles | $130.05B | $110.82B | $60.41B | $50.94B | +17.4% |
| Total assets | $542.90B | $465.63B | $314.49B | $241.26B | +16.6% |
| Total current liabilities | $215.66B | $217.61B | $169.66B | $120.94B | -0.9% |
| Current debt | $10.68B | $11.78B | $5.30B | $480.00M | -9.3% |
| Long-term debt | $111.70B | $84.25B | $15.98B | $20.77B | +32.6% |
| Total debt | $130.96B | $102.79B | $27.01B | $25.78B | +27.4% |
| Total liabilities | $348.86B | $322.14B | $207.93B | $157.77B | +8.3% |
| Retained earnings | $195.30B | $144.45B | $104.84B | $80.59B | +35.2% |
| Shareholder equity | $194.05B | $143.49B | $106.56B | $83.49B | +35.2% |
| Working capital | -$43.21B | -$55.83B | -$30.01B | -$12.75B | +22.6% |
| Net tangible assets | $63.99B | $32.66B | $46.16B | $32.55B | +95.9% |
| Shares issued | 4.46B | 4.46B | 4.51B | 4.56B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $102.43B | $100.99B | $83.68B | $55.52B | — | +1.4% |
| Depreciation & amortisation | $14.67B | $8.54B | $9.41B | $7.36B | — | +71.6% |
| Stock-based compensation | — | $2.29B | $2.15B | $1.54B | $1.04B | — |
| Change in working capital | $3.74B | $2.59B | $19.71B | -$5.54B | — | +44.3% |
| Operating cash flow | $119.10B | $120.97B | $108.91B | $78.89B | — | -1.5% |
| Capital expenditure | -$90.11B | -$51.31B | -$38.90B | -$14.75B | — | -75.6% |
| Investing cash flow | -$79.16B | -$128.90B | -$43.89B | -$24.92B | — | +38.6% |
| Share buybacks | -$1.39B | -$20.18B | -$29.92B | -$24.09B | — | +93.1% |
| Dividends paid | -$51.76B | -$44.14B | -$31.77B | -$25.30B | — | -17.3% |
| Financing cash flow | -$28.41B | $8.73B | -$63.16B | -$51.80B | — | -425.2% |
| Free cash flow | $28.99B | $69.66B | $70.01B | $64.13B | — | -58.4% |
| End cash position | $26.46B | $15.65B | $14.39B | $12.65B | — | +69.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $78.49B | $96.82B | $79.14B | $74.98B | $76.86B | -18.9% |
| Operating revenue | $78.49B | $96.82B | $79.14B | $74.98B | $76.86B | -18.9% |
| Cost of revenue | $17.10B | $13.60B | $15.15B | $17.90B | $12.85B | +25.8% |
| Gross profit | $61.39B | $83.22B | $64.00B | $57.07B | $64.01B | -26.2% |
| Research & development | $17.79B | $10.28B | $14.65B | $15.39B | $11.69B | +73.0% |
| Selling, general & admin | $16.31B | $13.22B | $17.44B | $17.88B | $18.85B | +23.4% |
| Total operating expense | $34.33B | $23.61B | $32.26B | $33.39B | $30.56B | +45.4% |
| Operating income | $27.06B | $59.62B | $31.74B | $23.68B | $33.45B | -54.6% |
| Net interest income | -$186.00M | $2.55B | $2.45B | $1.83B | $356.00M | -107.3% |
| Pre-tax income | $26.88B | $62.17B | $34.19B | $25.52B | $33.80B | -56.8% |
| Tax provision | $5.89B | $13.62B | $7.29B | $5.51B | $7.30B | -56.8% |
| Net income | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | -56.8% |
| Net income to common | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | -56.8% |
| Basic EPS | 4.74 | 10.93 | 6.06 | 4.50 | 5.96 | -56.6% |
| Diluted EPS | 4.74 | 10.91 | 6.04 | 4.50 | 5.96 | -56.6% |
| EBIT | $28.38B | $65.67B | $31.74B | $23.68B | $38.76B | -56.8% |
| EBITDA | $28.38B | $69.21B | $31.74B | $31.44B | $43.60B | -59.0% |
| Basic shares | 4.43B | 4.44B | 4.44B | 4.44B | 4.45B | -0.3% |
| Diluted shares | 4.44B | 4.45B | 4.45B | 4.45B | 4.45B | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.48B | $21.13B | $26.46B | $32.08B | $18.43B | +110.5% |
| Cash & short-term investments | $44.98B | $21.63B | $26.96B | $32.58B | $18.93B | +108.0% |
| Accounts receivable | $88.95B | $82.56B | $70.86B | $75.42B | $69.58B | +7.7% |
| Inventory | $51.35B | $51.35B | $49.62B | $47.50B | $45.65B | 0.0% |
| Total current assets | $208.70B | $177.32B | $172.45B | $181.88B | $162.71B | +17.7% |
| Property, plant & equipment | $231.76B | $219.97B | $208.38B | $193.24B | $180.76B | +5.4% |
| Goodwill & intangibles | $122.06B | $129.91B | $130.05B | $106.59B | $107.87B | -6.0% |
| Total assets | $594.94B | $559.22B | $542.90B | $512.29B | $482.15B | +6.4% |
| Total current liabilities | $239.08B | $225.16B | $215.66B | $234.36B | $207.52B | +6.2% |
| Current debt | $18.33B | $27.21B | $10.68B | $12.03B | $11.96B | -32.6% |
| Long-term debt | $121.79B | $119.17B | $111.70B | $89.18B | $87.31B | +2.2% |
| Total debt | $140.13B | $146.38B | $130.96B | $101.21B | $99.27B | -4.3% |
| Total liabilities | $373.66B | $356.16B | $348.86B | $342.39B | $314.09B | +4.9% |
| Retained earnings | $224.16B | $206.42B | $195.30B | $168.53B | $164.45B | +8.6% |
| Shareholder equity | $221.28B | $203.06B | $194.05B | $169.90B | $168.07B | +9.0% |
| Working capital | -$30.39B | -$47.84B | -$43.21B | -$52.48B | -$44.82B | +36.5% |
| Net tangible assets | $99.22B | $73.16B | $63.99B | $63.31B | $60.20B | +35.6% |
| Shares issued | 4.46B | 4.46B | 4.46B | 4.44B | 4.44B | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | -56.8% |
| Depreciation & amortisation | $10.30B | $3.54B | -$1.75B | $7.76B | $4.83B | +191.4% |
| Change in working capital | $13.32B | -$33.23B | $20.37B | -$9.16B | $7.94B | +140.1% |
| Operating cash flow | $55.20B | $24.08B | $7.62B | $44.98B | $41.77B | +129.2% |
| Capital expenditure | -$12.80B | -$12.04B | -$43.84B | -$15.41B | -$16.27B | -6.3% |
| Investing cash flow | -$12.76B | -$11.71B | -$42.81B | -$16.25B | -$14.12B | -9.0% |
| Share buybacks | -$3.50B | -$2.40B | $0 | $0 | $0 | -45.8% |
| Dividends paid | $0 | -$35.31B | $0 | -$16.66B | $174.00M | +100.0% |
| Financing cash flow | -$19.13B | -$17.43B | $29.47B | -$15.14B | -$47.35B | -9.7% |
| Free cash flow | $42.40B | $12.04B | -$36.22B | $29.56B | $25.50B | +252.0% |
| End cash position | $44.48B | $21.13B | $26.46B | $32.08B | $18.43B | +110.5% |
Options analytics
Put / call volume
0.48
Call-heavy session
Put / call open interest
0.38
Positioning, not flow
Max pain
38.00
+1.3% from spot
ATM implied vol
32.0%
Nearest strike to spot
Skew (10% OTM)
+30.9%
Puts bid over calls
Call volume
3.73K
Contracts, this expiry
Put volume
1.79K
Contracts, this expiry
Heaviest call OI
39.00
2.15K contracts
Heaviest put OI
37.00
1.19K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 4.98 | 6.18 | +24.0% |
| Mar 2026 | 6.96 | 6.63 | -4.8% |
| Dec 2025 | 5.90 | 6.04 | +2.3% |
| Sep 2025 | 4.24 | 4.50 | +6.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 4.83 | 4 | $73.13B | -2.5% |
| Next quarter | 4.56 | 4 | $74.56B | -5.8% |
| Current year | 22.73 | 8 | $300.29B | -2.8% |
| Next year | 22.10 | 8 | $304.17B | +1.3% |
Analyst targets & ownership
Mean target$46.14
High target$62.02
Low target$39.19
Implied upside22.94%
Analyst count12
ConsensusHOLD
Strong buy / Buy0 / 3
Hold10
Sell / Strong sell1 / 0
Held by insiders0.00%
Held by institutions9.89%
Institutions holding1.61K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
38.03
-1.32% from price
SMA 20
40.26
-6.79% from price
SMA 50
44.21
-15.11% from price
SMA 100
45.30
-17.16% from price
SMA 200
45.54
-17.59% from price
EMA 12
38.74
-3.13% from price
EMA 26
40.87
-8.16% from price
EMA 50
42.86
-12.44% from price
RSI (14)
28.6
Oversold
MACD (12,26,9)
-2.12
Hist -0.11
ATR (14)
1.01
2.69% of price
Realised vol 30D
36.3%
Annualised
Bollinger upper
45.34
20, 2σ
Bollinger lower
35.19
20, 2σ
50 / 200 cross
Death
44.21 vs 45.54
Trend bias
Below 200
-17.59%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.05
More volatile than market
Correlation to SPY
0.30
Largely independent
Realised vol 30D
36.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-44.8%
Peak to trough
Max drawdown 5Y
-76.0%
Peak to trough
ATR 14
1.01
2.69% of price
Beta (reported)
0.38
5Y monthly, from filing
Short interest
Shares short
26.34M
Prior 33.83M
Change vs prior
-22.1%
Shorts covering
% of float
0.83%
Normal
% of shares out
0.60%
Against total outstanding
Days to cover
2.5
Liquid
Float
3.17B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 11, 26 | Morgan Stanley | DOWNGRADE | Equal-Weight | Underweight |
| Mar 2, 26 | Goldman Sachs | DOWNGRADE | Buy | Neutral |
| Feb 24, 26 | JP Morgan | DOWNGRADE | Overweight | Neutral |
| Jan 9, 26 | CICC | INITIATED | — | Outperform |
| Dec 8, 25 | Argus Research | DOWNGRADE | Buy | Hold |
| Nov 28, 25 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Nov 25, 25 | BMO Capital | MAINTAINED | Market Perform | Market Perform |
| Nov 24, 25 | HSBC | DOWNGRADE | Buy | Hold |
| Oct 14, 25 | BMO Capital | MAINTAINED | Market Perform | Market Perform |
| Oct 2, 25 | HSBC | UPGRADE | Hold | Buy |
| Sep 29, 25 | Morgan Stanley | DOWNGRADE | Equal-Weight | Underweight |
| Sep 17, 25 | Berenberg | UPGRADE | Hold | Buy |
Dividends & splits
Forward rate$1.80 / yr
Forward yield4.79%
5-year avg yield1.49%
Payout ratio45.09%
Ex-dividend dateAug 17, 2026
Next pay dateAug 25, 2026
Last split2:1
Split dateSep 20, 2023
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-05
Corporate Changes & Voting Matters
6-K · 2026-09-28
Corporate Changes & Voting Matters
6-K · 2026-09-21
Corporate Changes & Voting Matters
6-K · 2026-09-17
Corporate Changes & Voting Matters
6-K · 2026-09-15
Corporate Changes & Voting Matters
6-K · 2026-09-09
Corporate Changes & Voting Matters
6-K · 2026-08-31
Corporate Changes & Voting Matters
6-K · 2026-08-24
Headlines
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Motley Fool · 2h ago
Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss
24/7 Wall St. · 10h ago
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
MT Newswires · 12h ago
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Zacks · 13h ago
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 13h ago
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Zacks · 15h ago
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Zacks · 15h ago
Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight
GlobeNewswire · 1d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.